PRA Health Sciences is a leader in conducting global oncology and hematology clinical trials. Over the past 5 years, PRA has participated in over 400 oncology and hematology projects involving over 47,000 patients across 9,200 clinical sites. They leverage evidence-based approaches and their network of over 50 in-house oncology experts to efficiently design and execute trials that advance the development of new drugs and therapies for cancer patients.

1. ONCOLOGY & HEMATOLOGY

2. EXPERIENCE
INNOVATION
Natural Hx of Disease
Subject Profiling
Rapid Online Feasibility
Site List Development
Investigator Identification
Country Selection
Recruit Rate Projections
Competitive Landscape
Site Volume Analysis
Pipeline Analysis
Investigator Grant Analysis
Leveraging Secondary
Health Data for Decision
Support in the Design
and Execution of Clinical
Research Studies
KOL Identification
Project Team Development
PRA leads the industry in advancing evidence-based approaches for the
successful start-up and conduct of clinical trials. Leveraging evidence-based
technology, we target the appropriate geographic areas for oncology
disease prevalence and identify a targeted list of oncology/hematology
investigators with the highest likelihood of accrual.
Approximately 60% of our medical directors have therapeutic expertise in oncology and
hematology. In addition, a high percentage of our global project management and clinical
operations team members are experienced in these indications, complementing their average
of 10+ years of study conduct experience.
EXPERTISE
In greater than
60% of instances,
our clients have
adjusted their
protocol design
and/or country
and site selection
based on our
evidence-based
data and therapeu-
tic experts’
recommendations.
MEDICAL DIRECTORS
=10%
CRAs PROJECT DIRECTORS
AND MANAGERS
CLINICAL TEAM MANAGERS
60 80 85 90
WITH ONCOLOGY/HEMATOLOGY EXPERIENCE
ONCOLOGY &
HEMATOLOGY
As a recognized leader in conducting complex, global oncology/hematology
trials, PRA has contributed to the approval of 12 important drugs. During the
last 5 years, PRA has participated in more than 400 oncology and hematology
clinical projects globally in every phase and virtually every indication,
including supportive care.
OUR ONCOLOGY
AND HEMATOLOGY
EXPERTS MAKE
THE COMPLEX,
SIMPLE.
PRA worked
on a drug that
extended survival
for breast cancer
patients that was
eventually FDA
approved. This
is what we are
all about – in
conjunction with
our sponsors –
delivering a better
quality of life
for patients.
PRA's global investigator network has enabled
us to establish preferred access to investigative
sites that are able to accrue patients and deliver
high-quality clinical trial data.
We never forget that every global oncology/hematology
study is executed locally. With global offices providing
service in 80+ countries, our team harnesses practical
knowledge of local regulations, standards of care and
cultural customs to maximize safety and efficiency for
your oncology trials.
“Our global footprint in traditional
markets – as well as emerging markets
– allows us to enroll patients rapidly
in oncology trials. This enables us to
bring our clients’ products to market
in a cost-effective way while optimizing
time and money during the drug
development process.”
DR. UTE BERGER MD
Sr. Vice President, Medical Affairs
No OF CLINICAL SITES*
9,200+
No OF CLINICAL STUDIES*
400+
No OF APPROVED DRUGS
12
*OVER THE PAST 5 YEARS
No OF CLINICAL PATIENTS*
47,250+

3. PRA Health Sciences conducts comprehensive phase I-IV biopharmaceutical drug development.
To learn more about our solutions, please visit us at prahs.com or email us at prahealthsciences@prahs.com.
Our commitment to advance oncology clinical development
is more than lip-service; today, we offer our clients access
to approximately 50 therapeutic experts in–house with
experience in conducting oncology clinical trials.
To save lives, or enable people to live better lives, is no small
thing. With every drug that we help bring to market, we not only
improve the lives of the individuals who need it, but also all the
lives that they touch. The ripples are countless, but the benefit
is clear. With each and every trial, we’re working with our clients
to change lives and to make the world a better place.
Our commitment to advance oncology/hematology clinical
development is more than lip-service; today, we offer our clients
access to approximately 50 in–house therapeutic experts with
experience in conducting oncology clinical trials.
To save lives, or enable people to live better lives, is no small
thing. With every drug that we help bring to market, we not only
improve the lives of the individuals who need it, but also all the
lives that they touch. The ripples are countless, but the benefit
is clear. With each and every trial, we’re working with our clients
to change lives and to make the world a better place.
PRA Health Sciences conducts comprehensive Phase I-IV biopharmaceutical drug development.
To learn more about our solutions, please visit us at prahs.com or email us at prahealthsciences@prahs.com.